Lenalidomide-d4

CAT: 0804-HY-A0003S3Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-A0003S3Size:1 Each
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Lenalidomide-d4 (CC-5013-d4) is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].
CAS Number
[1130061-52-7]
Product Name Alternative
CC-5013-d4
UNSPSC
12352005
Target
Apoptosis; Isotope-Labeled Compounds; Ligands for E3 Ligase; Molecular Glues
Related Pathways
Apoptosis; Others; PROTAC
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Smiles
O=C1N(C2C(NC(C([2H])([2H])C2([2H])[2H])=O)=O)CC3=C(N)C=CC=C31
Molecular Formula
C13H9D4N3O3
Molecular Weight
263.29
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Rozewski DM, et al. Pharmacokinetics and tissue disposition of lenalidomide in mice. AAPS J. 2012 Dec;14 (4) :872-82.|[3]Lopez-Girona A, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012 Nov;26 (11) :2326-35.|[4]Kotla V, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009 Aug 12;2:36.|[5]Omran A, et al. Effects of MRP8, LPS, and lenalidomide on the expressions of TNF-α , brain-enriched, and inflammation-related microRNAs in the primary astrocyte culture. ScientificWorldJournal. 2013 Sep 21;2013:208309.|[6]Nagashima, Takeyuki, et al. PHARMACEUTICAL COMPOSITION COMPRISING BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND AS ACTIVE INGREDIENT. Patent. 20170360780A1.|[7]Minzel W, et al. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell. 2018 Sep 20;175 (1) :171-185.e25.|[8]Krönke J, et al. Lenalidomide induces degradation of IKZF1 and IKZF3. Oncoimmunology. 2014 Jul 3;3 (7) :e941742.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-A0003-01Lenalidomide
HY-A0003ALenalidomide (hydrochloride)
HY-W039233-01Lenalidomide-F
HY-131318-01Lenalidomide-I
HY-43722-01Lenalidomide-Br
HY-A0003R-01Lenalidomide (Standard)
HY-133144-01Lenalidomide-OH
HY-132248-01C5 Lenalidomide
HY-A0003B-01Lenalidomide (hemihydrate)
HY-145461Hydroxy lenalidomide

Alternative Products

CatalogName
T1642-01Lenalidomide
M23571-01Lenalidomide-OH

Popular Products